Trial Profile
A multicenter, 6-week-treatment, open-label study assessing the percentage of hyperlipidemic patients achieving low density lipoprotein cholesterol target with atorvastatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms ACTFAST-SWISS
- Sponsors Pfizer
- 19 Nov 2005 New trial record.